Uridine triphosphate (UTP) |
| カタログ番号GC33830 |
ウリジン三リン酸 (UTP) (UTP; ウリジン 5'-三リン酸) は、内分泌および外分泌の分泌、増殖、チャネル、トランスポーター、および正常および疾患状態での細胞内シグナル伝達における膵臓の機能を調節するヌクレオチドです。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 63-39-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Uridine triphosphate (UTP;Uridine 5'-triphosphate) is a pyrimidine nucleoside triphosphate that participates in glycogen metabolism and synthesis of RNA during transcription.
Uridine triphosphate treatment induces Schwannoma cell migration through activation of P2Y2 receptors and through the increase of extracellular matrix metalloproteinase-2 (MMP-2) activation and expression[1]. Uridine triphosphate-induced proliferation is mediated by protein kinase D, Src-family tyrosine kinase, Ca/calmodulin-dependent protein kinase II, phosphatidylinositol 3-kinase (PI3K), Akt, and phospholipase D. Uridine triphosphate increases phosphorylation of Akt through protein kinase C, Src-family tyrosine kinase, Ca/calmodulin-dependent protein kinase II, and PI3K[2].
Uridine triphosphate reduces mitochondrial calcium levels following hypoxia. Early or late uridine triphosphate preconditioning is effective to reduce infarct size and superior myocardial function[3]. Uridine triphosphate treatment increases the number of monocytes and macrophages infiltrating the pouch and up-regulates the gene expression of IL-4 and IL-13 in the regional lymph nodes[4].
[1]. Lamarca A, et al. Uridine 5'-triphosphate promotes in vitro Schwannoma cell migration through matrix metalloproteinase-2 activation. PLoS One. 2014 Jun 6;9(6):e98998. [2]. Choi JH, et al. Uridine triphosphate increases proliferation of human cancerous pancreatic duct epithelial cells by activating P2Y2 receptor. Pancreas. 2013 May;42(4):680-6. [3]. Yitzhaki S, et al. Uridine-5'-triphosphate (UTP) reduces infarct size and improves rat heart function aftermyocardial infarct. Biochem Pharmacol. 2006 Oct 16;72(8):949-55. [4]. Iwaki Y, et al. Enhancement of antibody production against rabies virus by uridine 5'-triphosphate in mice. Microbes Infect. 2014 Mar;16(3):196-202.
Cell experiment: | Pancreatic duct epithelial cells are treated with (0.1 μM-1 mM) uridine triphosphate. BrdU is added after different time points (12-24 hours). Proliferation is measured using the BrdU incorporation assay in triplicate[2]. |
Animal experiment: | Rats: Four main groups are tested: (1) sham without LAD ligation, (2) LAD ligation, (3) injected with UTP (0.44 µg/kg i.v.) 30 min before MI, (4) UTP injection (4.4 µg/kg i.v.) 24 h prior to MI. Several different concentrations of UTP are tested (0.044–44.4 µg/kg). Left ventricular systolic pressure (LVSP), end-diastolic pressure (LVEDP) and heart rates are monitored before, after UTP treatment and post MI[3]. |
References: [1]. Lamarca A, et al. Uridine 5'-triphosphate promotes in vitro Schwannoma cell migration through matrix metalloproteinase-2 activation. PLoS One. 2014 Jun 6;9(6):e98998. | |
| Cas No. | 63-39-8 | SDF | |
| Canonical SMILES | O[C@H]1[C@H](N2C(NC(C=C2)=O)=O)O[C@H](COP(OP(OP(O)(O)=O)(O)=O)(O)=O)[C@H]1O | ||
| Formula | C9H15N2O15P3 | M.Wt | 484.14 |
| 溶解度 | Water : ≥ 150 mg/mL (309.83 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.0655 mL | 10.3276 mL | 20.6552 mL |
| 5 mM | 0.4131 mL | 2.0655 mL | 4.131 mL |
| 10 mM | 0.2066 mL | 1.0328 mL | 2.0655 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *